28 NOV 2017

UDG Healthcare plc
Preliminary Announcement of Results
Year ended 30 September 2017

Strong full year performance, driven by organic growth and further acquisitions

28 November 2017: UDG Healthcare plc (“UDG Healthcare” or “Group”), a leading international healthcare services provider, announces its preliminary results for the year ended 30 September 2017, which reflects another year of strong growth and strategic progress for the Group.

Download Results


Financial Results

 

IFRS

based 

$'m

Adjustments1

$'m

Adjusted

$'m

 

Increase/
(decrease)

on 2016

%

Constant

currency

increase

on 2016

%

Continuing operations     
Revenue 1,219.8 - 1,219.8 13 17
Net revenue2  1,028.5 - 1,028.5 12 16
Operating profit 103.2 26.1 129.3 12 17
Profit before tax 92.8 26.1 118.9 17 23
Diluted earnings per share (EPS) (cent) 28.83 8.29 37.12 17 23
Discontinued operations3   
Diluted earnings per share (cent) - - - (100) (100)
Total diluted earnings per share (cent) 28.83 8.29 37.12 (5) (1)
Dividend per share (cent) 13.30 - 13.30 7 7
           

 

  2017 2016
Net (debt)/cash ($’m) (53.3) 143.2
Net (debt)/cash/annualised EBITDA (times) (0.32) 1.05

1. Adjusted operating profit, profit before tax and diluted EPS are stated before the amortisation of acquired intangible assets ($22.1m, pre-tax) and transaction costs ($4.0m, pre-tax).

2. Net revenue represents gross revenue adjusted for revenue associated with pass-through costs, for which the Group does not earn a margin.

3. The Group has classified its joint venture arrangement with Magir Limited as a discontinued operation and an asset held for sale. The discontinued operations in 2016 also included United Drug Supply Chain Services, United Drug Sangers, TCP Group and MASTA. The Group’s disposal of these operations was completed on 1 April 2016.

Results Video

 

Download Results

View Webcast

Download Presentation

Download Investor Booklet

Download Infographic